INVICTUS HIRES INTERIM CHIEF MARKETING OFFICER AND EXPANDS INVESTOR RELATIONS
February 12 2019 - 8:30PM
INVICTUS MD STRATEGIES CORP. ("Invictus" or the "Company")
(TSXV: GENE; OTCQX: IVITF; FRA: 8IS1) is pleased to announce
that it has hired a prominent Toronto based strategic consulting
agency (the “Agency”) as interim Chief Marketing Officer (“interim
CMO”), strategic consulting partner, creative agency partner and
live events partner. The contract duration is six months and began
on January 1, 2019.With over 35 years of branding experience in the
healthcare sector, the Agency will leverage its expertise to help
create, develop, and execute the go-to-market strategy for Invictus
cannabis products. As interim CMO, the Agency will work with
Authentic Brands Group (“ABG”) and Invictus’ senior leadership team
to facilitate the anticipated launch of Invictus’ medical brand
T2C, and adult recreational brands under Dukes and Sterling &
Hunt.
Invictus will compensate the Agency with a monthly fee of
$45,000 CAD, payable in common shares of Invictus using a per share
issue price equal to the greater of: (i) the 30-day volume weighted
average price (“VWAP”) of the Company’s common shares on the TSX
Venture Exchange for December 2018 (adjusted for any share
consolidation of the Company); and (ii) the maximum discount
allowable under the TSX Venture Exchange policies on the date of
issuance.
To bolster the Company’s profile, Invictus has enlisted Darwin
Productions Inc. (“Darwin”) to provide investor relations and
marketing services. The Company’s contract with Darwin is for
$25,000 CAD per month. In addition, Darwin will provide a direct
mail scheduled for distribution in early March. This campaign will
cost approximately $500,000 USD and reach nearly 500,000 households
in North America, providing company information to build brand
awareness.
The Company has also granted 250,000 stock options to a certain
advisor of the Company. Each stock option has an exercise price of
$1.00 and is exercisable into one common share of the Company. The
options vest immediately and are exercisable over a period of five
years. The stock options were granted subject to the terms and
conditions of the Company's Stock Option Plan.For more information,
please visit www.invictus-md.com.
On Behalf of the Board,George E. KvetonChief Executive Officer
and DirectorJessica MartinVice President, Public Relations and
Regulatory Affairs(833) 879-4363About Invictus
Invictus is a global cannabis company offering a selection of
products under a wide range of brands. Our integrated sales
approach is defined by five pillars of distribution including
medical, adult-use, international, Licensed Producer to Licensed
Producer and retail stores.
Invictus has partnered with business leaders to convey our
corporate vision, including KISS music legend and business mogul
Gene Simmons as our Chief Evangelist Officer. To meet growing
demand, Invictus is expanding its cultivation footprint, with three
cannabis production facilities licensed under the Cannabis Act and
Cannabis Regulations in Canada. To accommodate international sales,
Invictus’ wholly-owned subsidiary, Acreage Pharms Ltd., has
designed and is currently building its Phase 3 purpose-built
cultivation facility to be European Union Good Manufacturing
Practices compliant. The Company is targeting for up to 50 percent
of its production to comprise medical cannabis. To ensure
consistency in quality and supply, Invictus maintains all aspects
of the growing process through its subsidiary, Future Harvest
Development Ltd., a high-quality fertilizer and nutrients
manufacturer. Invictus drives sustainable long-term shareholder
value through a diversified product portfolio with over 70 Health
Canada approved strains and a multifaceted distribution strategy
including medical, adult-use, international, Licensed Producer to
Licensed Producer and retail stores. For more information visit
www.invictus-md.com.
Cautionary Note Regarding Forward-Looking Statements: This
release includes certain statements and information that may
constitute forward-looking information within the meaning of
applicable Canadian securities laws or forward-looking statements
within the meaning of the United States Private Securities
Litigation Reform Act of 1995. All statements in this news release,
other than statements of historical facts, including statements
regarding future estimates, plans, objectives, timing, assumptions
or expectations of future performance, including the Company’s
launch of Invictus medical and adult recreational brands under T2C,
and Dukes and Sterling & Hunt, respectively, is a
forward-looking statement and contain forward-looking information.
Generally, forward-looking statements and information can be
identified by the use of forward-looking terminology such as
"intends" or "anticipates", or variations of such words and phrases
or statements that certain actions, events or results "may",
"could", "should", "would" or "occur". Forward-looking statements
are based on certain material assumptions and analysis made by the
Company and the opinions and estimates of management as of the date
of this press release, including that the Company will complete its
launch of Invictus medical and adult recreational brands under T2C,
and Dukes and Sterling & Hunt, respectively. This
forward-looking statement is subject to known and unknown risks,
uncertainties and other factors that may cause the actual results,
level of activity, performance or achievements of the Company to be
materially different from those expressed or implied by such
forward-looking statements or forward-looking information.
Important factors that may cause actual results to vary, include,
without limitation, that the Company will not complete its launch
of Invictus medical and adult recreational brands under T2C, and
Dukes and Sterling & Hunt, respectively. Although management of
the Company has attempted to identify important factors that could
cause actual results to differ materially from those contained in
forward-looking statements or forward-looking information, there
may be other factors that cause results not to be as anticipated,
estimated or intended. There can be no assurance that such
statements will prove to be accurate, as actual results and future
events could differ materially from those anticipated in such
statements. Accordingly, readers should not place undue reliance on
forward-looking statements and forward-looking information. Readers
are cautioned that reliance on such information may not be
appropriate for other purposes. The Company does not undertake to
update any forward-looking statement, forward-looking information
or financial out-look that are incorporated by reference herein,
except in accordance with applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services
Provider accepts responsibility for the adequacy or accuracy of
this release.
Jessica Martin
Invictus
647-828-9655
jessica@invictus-md.com
Invictus MD Strategies (TSXV:GENE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Invictus MD Strategies (TSXV:GENE)
Historical Stock Chart
From Sep 2023 to Sep 2024